Withus Pharmaceutical Co (330350.KQ) Stock Price

Withus Pharmaceutical Co Price

CLOSED
6,500.00
​
Market closed

Revenue has compounded at 9.6% per year over the past 8 years to 106.44 B KRW. Earnings per share have declined at 8.0% per year over the last 8 years. Withus Pharmaceutical Co's net margin stands at 4.7%, down from 7.4% several years earlier. Withus Pharmaceutical Co currently offers a dividend yield of about 1.54%. The payout ratio is around 27% of earnings.

Withus Pharmaceutical Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Withus Pharmaceutical Co business model & stock analysis

Withus Pharmaceutical Co Ltd is a pharmaceutical company based in Seoul, South Korea, operating within the healthcare sector. The company focuses on the manufacturing and distribution of prescription drugs, with its headquarters located in Seoul. As of the latest available information, Withus Pharmaceutical employs 191 full-time staff members. The company completed its initial public offering (IPO) on July 3, 2020, marking its entry into the public market. Its primary product categories include circulatory agents, musculoskeletal agents, digestive agents, antibiotics, and other prescription medications. Additionally, the company engages in contract manufacturing operations (CMO), providing manufacturing services for other pharmaceutical entities. Withus Pharmaceutical maintains a corporate website at https://www.withuspharm.com/mastart/mastart.php, which serves as a platform for company information and updates. The company operates in the pharmaceutical industry, contributing to the production and supply of essential medications in South Korea. Withus Pharmaceutical's business model integrates both direct product sales and contract manufacturing services, supporting its role in the broader healthcare ecosystem. The company's operations are centered around the development and delivery of prescription drugs, with a focus on key therapeutic areas such as cardiovascular health, musculoskeletal conditions, gastrointestinal treatments, and infectious disease management. The firm's activities are conducted under the regulatory framework of South Korea's pharmaceutical industry, adhering to local standards for drug manufacturing and distribution.

Frequently asked questions about Withus Pharmaceutical Co

Converted at the current exchange rate, the Withus Pharmaceutical Co share trades at 4.42 EUR (6,500.00 KRW).

The revenue cannot currently be calculated for Withus Pharmaceutical Co.

The profit cannot currently be calculated for Withus Pharmaceutical Co.

The P/E ratio cannot be calculated for Withus Pharmaceutical Co at the moment.

The P/S cannot be calculated for Withus Pharmaceutical Co currently.

The Eulerpool Quality Score for Withus Pharmaceutical Co is 5/10.

The ISIN of Withus Pharmaceutical Co is KR7330350000. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Withus Pharmaceutical Co is 330350.KQ. The ticker symbol is used to trade Withus Pharmaceutical Co shares on the stock exchange.

Fair ValueTerminal
5,330.00 KRW
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
557.30 M KRW
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
South Korea
Currency
KRW
Initial public offering
Jul 3, 2020
ISIN
KR7330350000
Cusip
Y9673H102
Market capitalization
85.80 B KRWLarge Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
15.15
P/B Ratio
0.88
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
5.07 %
Dividend
Dividend yield
0.00 %
Payout Ratio
31.32 %
Dividend growth Ø5Y
—
Dividend payments per year
1
Dividend paid since
0 years
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
22.00 %
Last updated Nov 22, 2026, 3:44 AM

Withus Pharmaceutical Co Peer Group

Withus Pharmaceutical Co FIGI

330350:KS · BBG003QVG9F3330350:KQ · BBG00V3L19C7